WEBINARS FOR HEALTHCARE PROFESSIONALS

Live Webinars

REGISTER

On-Demand Webinars

WATCH VIDEOS

What We've Learned From the COVID-19 Pandemic: A Panel Discussion

The livestream will feature learnings over the last year in the world of diabetes including the need for data and technology in diabetes management, telehealth now and moving forward, disparities and equity in diabetes, followed by live Q&A with the panel.

Panelists:

  • Diana Isaacs, PharmD, CDCES CGM Program Coordinator, Cleveland Clinic
  • David Kerr, MD, Director of Research and Innovations, Sansum Research Institute
  • Osagie Ebekozien, MD, MPH, VP, Quality Improvement & Population Health, T1D Exchange
  • Robert Vigersky, MD, Chief Medical Officer, Medtronic Diabetes

REGISTER

Livestream Event

Healthcare professional holding an appointment via a laptop

Smart Pen Technology

Determining and Fine-Tuning Insulin Therapy Settings for Smart Insulin Delivery

This webinar reviews guidelines on calculating and adjusting individualized therapy settings for your patients for smart insulin pens, followed by Q&A.

Speakers: Jennifer Okemah, MS, RDN, CSSD, BC-ADM, CDE, Salute Nutrition, PLLC & Erica Kretchman, DO, Reid Endocrinology Center

WATCH VIDEO

Diabetes Technology: Shared Decision Making Leads to Informed Therapy Decisions

This webinar teaches you how to help your patients get off to a strong start with new technology tools and how to collaborate to foster ongoing engagement, followed by Q&A.

Speaker: Erica Kretchman, DO, Reid Endocrinology Center

REGISTER
InPen and the Guardian Sensor.

The Training Success Kit: A Webinar Series for Educators

This webinar series is intended for Educators and Certified Product Trainers to offer insightful and practical education on Medtronic therapies and technologies.

Webinar 1: Training Patients on the MiniMedTM 770G System: What We’ve Learned So Far

Speaker: Karol Matson, MS, RD, CDCES, Senior Clinical Territory Manager

WATCH VIDEO

Webinar 3: Using the MiniMedTM 770G Virtual Pump

Speaker: Michelle Wirthgen, RN, CDCES, Principal Clinical Territory Manager

WATCH VIDEO

Webinar 2: The MiniMedTM 770G System: Apps and Connectivity Insights

Speaker: Lyndsay Gregerson, RD, CD, CDCES, Principal Clinical Territory Manager

WATCH VIDEO
A medical professional sits and shows charts to their patient.

HYBRID CLOSED LOOP THERAPY

ABCs of Managing Patients on the MiniMedTM 770G System

This webinar reviews assessing SmartGuard™ Auto Mode, coaching patient behaviors, and making clinician changes, followed by Q&A.

Speaker: Jennifer Osipoff, MD, FAAP, Stony Brook Children’s Hospital

REGISTER

MiniMedTM 770G System: Situations for Special Consideration

This webinar reviews using the MiniMed™ 770G system to assess situations requiring special considerations, including exercise, high-fat meals, sick days, steroids and outpatient procedures, followed by Q&A.

Speaker: Jennifer McVean, MD, University of Minnesota, Masonic Children’s Hospital

REGISTER
The MiniMed 770G insulin pump system.

insulin pump therapy for type 2 diabetes

Insulin Pump Therapy: A Clinical-Evidence Based Approach

This webinar reviews the evidence behind insulin pump therapy for people with type 2 diabetes, followed by Q&A.

Speaker: James Thrasher, MD, FACE, Arkansas Diabetes and Endocrine Center

REGISTER

Fine-Tuning Pump Settings

This webinar reviews patient instructions for the adjustment phase, guidelines for evaluating CareLink™ data and adjusting settings, and case study examples, followed by Q&A.

Speaker: Brian Lake, DO, Lake Endocrinology & Diabetes

REGISTER
MiniMed 630 pump, sensor, and glucose meter on white background

INNOVATIONS

Transforming the Future of Diabetes Care including Smart Pen Technology, CGM and Automated Systems

This webinar is a live discussion on the outcomes of the current Medtronic portfolio, smart pen technology, sensor innovation goals, and advancing therapy with closed-loop algorithms and integrated systems, followed by Q&A.

Speaker: Medtronic Engineer

REGISTER

Virtual Endocrine Fellows 4-Course Webinar Series

These course offerings are intended for Endocrine Fellows who are looking to gain additional educational opportunities in the diabetes space. Each course offering will provide fellows with the opportunity to learn and engage with key opinion leaders around the use of Medtronic therapies and technologies.

Webinar 1: Clinical Footprint for the Future of Diabetes Management 

Speakers: Robert Vigersky, MD & Andrew S. Rhinehart, MD, FACP, FACE, CDCES, BC-ADM

WATCH VIDEO

Webinar 3: Therapy Optimization with CareLinkTM Software

Speaker: Amit Bhargava, MD, FACSc

Webinar 2: Hybrid Closed Loop Therapy

Speaker: Joshua Miller, MD, MPH

Webinar 4: Transforming Diabetes Care and the Patient Experience

Speaker: Lou Lintereur, Distinguished Engineer

Important Safety Information: MiniMedTM 770G System with SmartGuardTM Technology

The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed™ 770G system consists of the following devices: MiniMed™ 770G insulin pump, the Guardian™ Link (3) transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the Accu-Chek® Guide test strips. The system requires a prescription.

The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).

All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.

WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode.

WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library

Important Safety Information: MiniMed™ 630G System with SmartGuard™ technology

Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G or MiniMed™ 530G system are not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.

WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.

See www.medtronicdiabetes.com/importantsafetyinformation and the appropriate user guides for additional important details.

IMPORTANT SAFETY INFORMATION FOR INPEN™ SMART INSULIN PEN:

The InPenTM requires a prescription. It is a home-use reusable pen injector for single-patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self-injection of a desired dose of insulin. The pen injector is compatible with Lilly Humalog® U-100 3.0 mL cartridges, Novo Nordisk Novolog® U-100 3.0 mL cartridg- es, and Novo Nordisk Fiasp® U-100 3.0 mL cartridges and single-use detachable and disposable pen needles (not included). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in one-half (1/2) unit increments.

The InPenTM dose calculator, a component of the InPenTM app, is indicated for the management of diabetes by people with diabetes under the supervision of an adult caregiver, or by a pa- tient age 7 and older for calculating an insulin dose or carbohydrate intake based on user entered data.

For an insulin dose based on amount of carbohydrates, a healthcare professional must provide patient-specific target blood glucose, insulin-to-carbohydrate ratio, insulin sensitivity pa- rameters, and duration of insulin action to be programmed into the software prior to use as it is required for set up.

For an insulin dose based on fixed/variable meal sizes, a healthcare professional must provide patient-specific fixed doses/meal sizes to be programmed into the software prior to use.

For additional product and important safety considerations, see User Guide and http://bit.ly/InPenSafety.

Ascensia Diabetes Care Logo

Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.”

©2021 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.